Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Fusco, Manuela Di; Marczell, Kinga; Deger, Kristen A; Moran, Mary; Wiemken, Timothy; Cané, Alejandro; Boisvilliers, Solène de; Yang, Jingyan; Vaghela, Shailja; Roiz, Julie

doi:10.1080/13696998.2022.2071427

Cited by 17 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the individual level, vaccines are key to preventing severe COVID-19, as unvaccinated individuals are more likely to be hospitalized and die from COVID-19. 20,21 People who smoke are at higher risk for chronic respiratory conditions, such as asthma, chronic obstructive pulmonary disease, and lung cancer. 22 Because their lungs are already vulnerable to disease, adults who smoke should be targeted with additional rigor through public health initiatives, like vaccine drives, or their health care providers to promote vaccine uptake.…”

Section: Current Studymentioning

confidence: 99%

COVID-19 Vaccine Hesitancy by Smoking Status Among Ohio Adults

Bhandari,

Teferra,

Nau

et al. 2024

OJPH

View full text Add to dashboard Cite

Background: Research in other countries and limited findings in the United States suggest that adults who smoke are less likely to get COVID-19 vaccines. The objective of this study was to examine vaccine hesitancy by smoking status in Ohio.Methods: We performed a secondary analysis of multiple 8-week waves of the Ohio COVID-19 Survey (OCS) from March 2021 to July 2022. The OCS participants comprised a subsample from the 2019 Ohio Medicaid Assessment Survey, a statewide health survey. After the COVID-19 vaccine was available, participants were asked about vaccination status and, among those not vaccinated, vaccine intentions. To compare vaccine hesitancy by smoking status, multivariable survey-weighted logistic regression models were fit, adjusted for potential confounders. Reason for vaccine hesitancy was asked using an open-ended question; data were coded and analyzed descriptively.Results: Adults who smoked, compared to those who never smoked, had significantly higher odds of being vaccine hesitant between March and April 2021, June and August 2021, October and November 2021, and May and July 2022, with odds ratios ranging from 1.60 to 2.44. Reasons for vaccine hesitancy were not different by smoking status.Conclusion: Although the difference in hesitancy by smoking status was attenuated after December 2021, coincid-ing with an increase in cases, evidence from summer 2022 indicates that adults who smoked continued to display vaccine hesitancy. These results have implications for COVID-19-related outcomes and more research is needed to understand reasons for vaccine hesitancy, which could also serve to educate adults who smoke about vaccination for other diseases.

show abstract

Section: Current Studymentioning

confidence: 99%

COVID-19 Vaccine Hesitancy by Smoking Status Among Ohio Adults

Bhandari,

Teferra,

Nau

et al. 2024

OJPH

View full text Add to dashboard Cite

show abstract

“…In the first year of Comirnaty® rollout, it is estimated that the vaccine contributed to averting almost 9 million symptomatic cases, 700,000 hospitalizations, and over 110,000 deaths. 33 This was made possible by progressing our vaccine development program swiftly, going from the first 10 mL IVT reaction run to the first drug product lot with an EUA in 3 months ( Figure 5 ). Our team and collaborators did this while successfully ensuring the highest compliance and quality standards according to the normal vaccine development principles: 19 1.…”

Section: Conclusion and Future Outlookmentioning

confidence: 99%

The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists’ Perspective

Lewis

Badkar

Cirelli

et al. 2023

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…In another mRNA vaccine study of COVID-19associated hospitalization of immunocompromised patients, the rate was 77% among immunocompromised adults than immunocompetent adults (90%) [42]. A survey by Pfizer investigators [45] which comprised data from 10 studies done in four countries between December 2020 and September 2021, showed vaccine effectiveness (VE) of 64% to 90% against SARS-CoV-2 infection, 73% to 84% against symptomatic illness, 70% to 100% against severe illness and 63% to 100% against COVID-19 related hospitalization among the fully vaccinated immune-compromised (IC) population. In an extensive study of 10 states covering a period of March 2020-February 2022, of 22345 adults hospitalized for COVID-19, 12.2% were organs, tissues, and kidneys that could complicate conditions of preexisting diabetes or lead to new mechanisms of disease [30].…”

Section: Immunocompromised Patientsmentioning

confidence: 99%

Coronavirus (COVID-19) Pandemic – A Comprehensive Review of Demographics, Comorbidities, Vaccines, Therapeutic Development, Blood Type, and Long Covid

Bhattacharyya¹,

Anand²,

N³

2023

Ann Public Health Reports

View full text Add to dashboard Cite

In late December 2019, a series of pneumonia cases of unknown origin emerged in China, with clinical presentations resembling viral pneumonia. Deep sequencing analysis of lower respiratory tract samples indicated a novel coronavirus named 2019 (2019-nCoV), causing a worldwide concern [1]. In March 2020, the 'severe acute respiratory syndrome coronavirus 2' (SARS-CoV-2) virus was declared a global pandemic. COVID-19, officially named by World Health Organization (WHO), had a case count of over 21M (21,010,700), with 761,260 deaths as of August 14, 2020, and over 603M (603,336,130) total cases, and over 6M (6,491,951) deaths as of August 2022 according to Johns Hopkins Coronavirus Resource Center [2]. The United States had the highest number of cases at 5,280,315 and a death

show abstract

Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Cited by 17 publications

References 42 publications

COVID-19 Vaccine Hesitancy by Smoking Status Among Ohio Adults

COVID-19 Vaccine Hesitancy by Smoking Status Among Ohio Adults

The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists’ Perspective

Coronavirus (COVID-19) Pandemic – A Comprehensive Review of Demographics, Comorbidities, Vaccines, Therapeutic Development, Blood Type, and Long Covid

Contact Info

Product

Resources

About